We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.025 | 2.04% | 1.25 | 4,355,482 | 13:21:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.20 | 1.30 | 1.25 | 1.20 | 1.225 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.23 | 9.31M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:36:47 | O | 45,000 | 1.2945 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/4/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Notice of Results |
| 21/2/2024 | 12:36 | ALNC |  Shield Therapeutics sinks as strong performance marred by data issues |
| 21/2/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Unaudited Full Year Trading Update |
| 09/1/2024 | 11:33 | ALNC | IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO |
| 09/1/2024 | 07:00 | UKREG | Shield Therapeutics PLC Appointment of new Chief Financial Officer |
| 07/12/2023 | 15:31 | ALNC | TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract |
| 07/12/2023 | 07:00 | UKREG | Shield Therapeutics PLC Q3 2023 U.S. Commercial Highlights |
| 27/11/2023 | 17:24 | UKREG | Shield Therapeutics PLC PDMR Transaction Notification |
| 20/10/2023 | 11:45 | RNSNON | Shield Therapeutics PLC Abstract to be presented at Healthcare Conference |
| 12/10/2023 | 11:14 | ALNC | IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave |
Shield Therapeutics (STX) Share Charts1 Year Shield Therapeutics Chart |
|
1 Month Shield Therapeutics Chart |
Intraday Shield Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/4/2024 | 13:28 | Shield Therapeutics: poised for a US licensing deal | 13,700 |
| 28/2/2024 | 13:05 | Shield Therapeutics | 4,111 |
| 22/2/2024 | 08:59 | Shield therapeutics what next? | 1,974 |
| 22/2/2024 | 08:37 | Shield Therapeutics: Poised for a US deal | 1 |
| 12/4/2023 | 10:06 | Shorted to 10p | 454 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 12:36:48 | 1.29 | 45,000 | 582.53 | O |
| 12:32:02 | 1.29 | 38,165 | 494.05 | O |
| 12:31:35 | 1.30 | 93,822 | 1,214.99 | O |
| 12:30:56 | 1.30 | 55,000 | 712.25 | O |
| 12:21:08 | 1.25 | 100,000 | 1,247.50 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Shield Therapeutics Daily Update Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 1.23p.Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £9,305,152. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.23. This morning STX shares opened at 1.23p |
Posted at 26/4/2024 11:04 by washingmachine ReviewI’ve scrolled right back on the thread You were Uber bullish like everyone else on here , the share price at the time was over 6 pence Only two names were fighting against the tide at the time Who were both lambasted and ridiculed by the thread Wally and Amaretto Scroll back , very sobering. R/W L at Price today |
Posted at 25/4/2024 12:20 by qipincha I don’t think share price is always a good indicator, especially for SMEs, the price can be easily manipulated. |
Posted at 25/4/2024 11:09 by ih_676530 The share price is heavily oversold on the tech chart,especially after today's drop. This should draw in value and chart traders. If Tuesday's results are as good as February's trading update then the share price could easily double in value in a single day. |
Posted at 25/4/2024 08:00 by r9505571 Consensus revenue estimates fall by 19%The consensus outlook for revenues in fiscal year 2023 has deteriorated.2023 revenue forecast decreased from US$15.3m to US$12.4m.Forecast losses increased from -US$0.037 to -US$0.039 per share.Pharmaceutical |
Posted at 04/4/2024 18:19 by bolitix Now i lost lots to these clowns so have now written that loss off. I did say this CEO would drag this share price near a penny some time ago. Now the worst could well be on the cards if they do a share exchange for the new company on a 1:10, 1:100 or even 1:1000 ratio to hype the price up on a Par so if 1:1000 the share price per share will be increased by a factor of 1000 to compensate but that will immediately drop lower. Hence, stay away from this company until it changes this CEO and its mindset. |
Posted at 06/3/2024 14:56 by sam_ From another STX chat board:“ we have several major shareholders, each holding less than 5% of the company's shares. This percentage serves as the requisite threshold for UK companies to inform the market of any changes in their holdings through a TR1 notification. Jupiter Asset Management Ltd 4.364 % Premier Fund Managers Ltd. 3.836 % LGT Capital Partners AG (Investment Management) 3.669 % KW Investment Management Ltd. 2.641 % Jarvis Investment Management Ltd. 1.680 % Given the substantial number of shares traded at the end of last month, I am inclined to believe that at least two major shareholders have offloaded their shares to the market and cashed out. Regardless, the past is behind us, and we've observed a nice buying momentum gaining traction since the start of this week. I can see the share price smoothly rise back to the 4s from its current level. The technical chart is currently indicating a significant oversold condition on both the weekly and daily charts, making it an appealing prospect for chart and momentum traders as well.” |
Posted at 27/2/2024 15:05 by bolitix I said a couple of months ago this CEO will take this below 1p share price Even with a 200% sales gain over 2023 he has managed to take the share price down 25 fold to date. VTRS share price is about 13p and i dont know AOPs but which of these who take over we cant expect the share price to ever top theirs. Now i am not gloating here as i have lost lots on STX! |
Posted at 23/2/2024 15:38 by base7 Greg talks a great story but has delivered an almost 100% write down in our share price since he took control.Our share price was recovering nicely at 12/13p until the disastrous 8p raise accompanied by disgraceful & obvious insider trading.AS ever, The Regulator did nothing & those shorting got away with it again.This weeks debacle of over stated prescription targets was another disgrace & either Greg of the CFO should have had an eye or two on that ball-resulting in cashflow break even being pushed back another 6-12 months & Greg & Santosh saying with confidence that we have sufficient cash to achieve that target must be taken with a pinch of salt or our share price would have recovered to the heady heights of 5p.Greg has been in situ for long enough to sort out Norgine but they continue plodding along doing very little with their rights to sell our products in a market of 500m potential patients - surely we should potentially generate more revenue from Europe than US. The only near term prospective good news is from Korea & Canada where we should soon be generating revenue - although that too is already several months behind schedule. The only other action Greg & Santosh could now take to give The Market a sign of their confidence is to invest a relatively small amount of their large packages on a substantial number of share + take some of their remuneration in shares.If I was running a company which I had total belief in I would want as many shares as possible-especially with our share price at a 60%+ discount to the 8p raise . Rant over - fine weekend to you all ! |
Posted at 19/12/2023 15:07 by bolitix It really does not matter what the rest of the worlds sales do. They know the US lates sales are actually 36% down pro-rata on the 22 sales team they had 4Q22 and this CEO pitiful upbeat sales pitch, even though prescriber access went up nearly 4 fold, is typical reason on his watch this share price demise from 56p on his take-over. Hence, until we get rid of this clowns's agenda to drain salaries out of the share rather than pursue profit this share price will simply struggle. |
Posted at 06/12/2023 10:00 by cyberbub I would have thought that AOP's average must be around 10p? If so, they won't sell out for less than 30p IMO. Who knows, if we see STX still making solid progress in the next update in January (especially if the GTN is increasingly rapidly) then the share price could easily jump to 15p-20p, and then is the moment for a bigger fish to pounce on us IMO, and offer 30p. Of course the share price could hit 40-50p in a couple of years time if all goes well, but I think a lot of shareholders (including me) would be happy to have a bird in the hand... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
